All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On May 22, 2023, the U.S. Food and Drug Administration (FDA) approved avapritinib for the treatment of patients diagnosed with indolent systemic mastocytosis.1 This approval was supported by results from the randomized phase II PIONEER trial (NCT03731260), which showed avapritinib plus best supportive care significantly improved outcomes for patients versus best supportive care alone.1
Your opinion matters
Avapritinib granted FDA priority review of sNDA for the treatment of indolent SM
The MPN Hub summarizes the recent FDA approval to the supplemental drug application for avapritinib for the treatment of indolent systemic mastocytosis.
Educational theme | Treating systemic mastocytosis
Within this Educational Theme, our second article focuses on the treatment of systemic mastocytosis (SM), a rare hematologic malignancy where abnormal neoplastic mast cells accumulate in...
Subscribe to get the best content related to MPN delivered to your inbox